샘플 요청 목록

 카트 문의
시장보고서
상품코드
1788259

펩티드 약물 접합체 시장

Peptide Drug Conjugates
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 282 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 펩티드 약물 접합체 시장은 2030년까지 95억 달러에 달할 전망

2024년에 36억 달러로 추정되는 세계의 펩티드 약물 접합체 시장은 2024-2030년에 CAGR 17.5%로 성장하며, 2030년에는 95억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 Pluvicto는 CAGR 16.1%를 기록하며, 분석 기간 종료시에는 38억 달러에 달할 것으로 예측됩니다. 옥트레오스캔(OctreoScan) 분야의 성장률은 분석 기간의 CAGR로 18.3%로 추정됩니다.

미국 시장은 9억 8,600만 달러로 추정, 중국은 CAGR 22.9%로 성장 예측

미국의 펩티드 약물 접합체 시장은 2024년에 9억 8,600만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 21억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 22.9%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 13.2%와 15.7%로 예측됩니다. 유럽에서는 독일이 CAGR 약 13.9%로 성장할 것으로 예측됩니다.

세계의 펩티드 약물 접합체 시장 - 주요 동향과 촉진요인 정리

펩티드 약물 접합체란?

펩티드 약물 접합체(PDC)는 펩티드의 치료적 특성과 약물 분자의 표적 전달 능력을 결합한 바이오의약품의 한 유형입니다. 이러한 컨쥬게이트는 특정 수용체나 바이오마커에 대한 특이성이 높은 생리활성 펩티드를 일반적으로 안정적인 화학적 결합을 통해 세포독성 또는 치료제물과 결합시켜 형성됩니다. PDC의 주요 목적은 펩티드를 통해 종양이나 감염 조직 등의 작용 부위에 직접 약물을 전달하여 부작용을 최소화하면서 치료 효과를 높이는 것입니다. 이러한 표적 전달 기전을 통해 약물이 건강한 조직을 보존하면서 병변 세포에만 특이적으로 작용하여 전신 독성을 줄이고 치료 효과를 높일 수 있습니다.

PDC에서 펩티드의 사용은 특정 세포 수용체에 선택적으로 결합하는 능력에 의해 촉진되어 표적 치료의 이상적인 후보입니다. 예를 들어 암 치료에서는 특정 수용체나 효소 등의 바이오마커를 과발현하는 종양세포에 직접 세포독성 약물을 전달하도록 PDC를 설계할 수 있습니다. 이러한 바이오마커를 인식하는 펩티드를 이용함으로써 PDC는 화학요법제나 면역조절제 등의 강력한 약물전달을 가능하게 하여 약물의 치료지수를 높입니다. PDC는 종양학, 자가면역질환, 감염질환 등의 분야에서 유망 치료제로서 기존의 전신 약물요법을 대체할 수 있는 보다 효과적이고 독성이 낮은 치료법을 제공합니다.

펩티드 약물 접합체 시장이 확대되는 이유는?

펩티드 약물 접합체 시장은 암 및 기타 만성질환의 유병률 증가, 표적 치료에 대한 수요 증가, 펩티드 기반 신약 개발의 발전 등 여러 요인으로 인해 빠르게 성장하고 있습니다. 시장 확대의 가장 큰 촉진요인 중 하나는 전 세계 암 발병률 증가입니다. 화학요법이나 방사선 치료와 같은 기존 치료법은 심각한 부작용을 유발하는 경우가 많기 때문에 보다 정밀하고 전신에 미치는 영향이 적은 치료법에 대한 요구가 증가하고 있습니다. PDC는 암세포를 선택적으로 표적화할 수 있으며, 기존 화학요법에 비해 부작용이 적고, 보다 효과적인 치료가 가능합니다.

맞춤형 의료로의 전환도 펩티드 약물 접합체 시장의 성장을 가속하는 중요한 요소입니다. 맞춤의료란 환자의 유전적 체질과 질환의 특성에 따라 환자 개개인에 맞는 치료를 하는 것을 말합니다. 펩티드는 높은 특이성과 고유한 바이오마커를 표적으로 하는 능력을 가지고 있으며, 개인 맞춤형 치료에 적합합니다. PDC는 특정 암세포 마커와 수용체를 인식하고 결합할 수 있는 펩티드를 사용함으로써 환자 개개인에 맞는 보다 효과적인 치료 전략을 가능하게 합니다. 이러한 개인 맞춤형 표적치료에 대한 관심은 앞으로도 펩티드 약물 접합체에 대한 관심과 투자를 촉진할 것으로 보입니다.

펩티드 기반 신약개발 기술 및 컨쥬게이션 기술의 발전도 PDC 시장 성장에 기여하고 있습니다. 펩티드 합성 및 컨쥬게이션 기술 연구가 계속 발전함에 따라 표적에 대한 높은 친화력을 가진 펩티드의 개발이 더 쉬워지고 비용 효율성도 향상되고 있습니다. 또한 펩티드와 약물 분자를 연결하는 링커 화학의 개선으로 PDC의 안정성, 유효성, 안전성 프로파일이 향상되었습니다. 이러한 발전으로 다양한 질환에 사용할 수 있는 새로운 PDC 치료법 개발이 가능해져 펩티드 약물 접합체의 응용 가능성이 더욱 넓어지고 있습니다.

펩티드 약물 접합체의 미래를 형성하는 주요 동향은 무엇인가?

펩티드 약물 접합체의 미래는 펩티드 합성 및 접합 기술의 발전, 병용요법의 부상, 비암 영역에서의 PDC 적용 확대 등 몇 가지 중요한 동향에 의해 형성되고 있습니다. 중요한 동향 중 하나는 펩티드 합성 및 컨쥬게이션 기술의 지속적인 향상입니다. 고체상 펩티드 합성(SPPS)과 자동 접합법의 개발로 고품질 펩티드의 생산과 보다 정교한 PDC의 개발이 가능해졌습니다. 이러한 발전은 펩티드 약물 접합체의 확장성에도 기여하고 있으며, 임상 사용을 위해 보다 효율적으로 제조할 수 있도록 돕고 있습니다.

또 다른 중요한 추세는 병용요법에서 PDC의 사용 증가입니다. 펩티드 약물 접합체를 면역관문억제제, 모노클로널 항체, 기존 화학요법 등 다른 치료법과 병용하는 병용요법이 활발히 진행되고 있습니다. 이러한 병용요법은 여러 경로를 표적으로 삼거나 암과 싸우는 면역체계의 능력을 향상시킴으로써 전반적인 치료 결과를 개선할 수 있도록 설계되었습니다. PDC와 다른 치료법의 병용요법의 시너지 효과는 특히 치료가 어려운 암에서 반응률 개선, 내성 감소, 장기 예후 개선으로 이어질 수 있습니다.

암 이외의 질환에 대한 PDC의 적용 확대도 이 시장 전망를 형성하고 있습니다. PDC는 지금까지 주로 암 분야에 집중되어 왔지만, 자가면역질환, 감염질환, 심지어 신경질환 치료에도 사용하려는 관심이 높아지고 있습니다. 펩티드 약물 접합체가 질병 부위를 보다 정교하게 표적화할 수 있는 능력은 고도로 표적화된 치료적 개입이 필요한 질병 치료의 새로운 길을 열어줄 수 있습니다. PDC의 광범위한 적용에 대한 연구가 진행됨에 따라 세계 산업 분석가들은 이러한 치료법이 더 다양한 임상 적응증에 사용될 것으로 기대하고 있습니다.

펩티드 약물 접합체 시장의 성장 촉진요인은?

펩티드 약물 접합체 시장의 성장은 표적 치료에 대한 수요 증가, 펩티드 기반 신약 개발의 발전, 효과적인 암 치료에 대한 세계 수요 증가 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 가장 중요한 촉진요인 중 하나는 전 세계 암 발병률 증가로, 암세포를 보다 선택적으로 표적화할 수 있는 치료법으로의 전환을 촉진하고 있습니다. 기존의 화학요법은 효과적이지만 특이성이 없기 때문에 종종 심각한 부작용을 유발하는 경우가 많습니다. 펩티드 약물 접합체는 약물을 종양 부위에 직접 전달함으로써 부작용이 적고, 보다 효과적인 치료 가능성을 제공하여 암과 싸우는 데 있으며, 매우 매력적입니다.

펩티드 합성 기술과 약물 결합 기술의 발전도 시장을 주도하고 있습니다. 보다 효율적이고 비용 효율적인 제조법 개발 등 펩티드 합성 기술의 향상으로 표적 바이오마커에 대한 특이성과 친화력이 높은 펩티드의 제작이 용이해졌습니다. 또한 약물과 펩티드를 보다 효과적으로 결합시키는 새로운 링커 기술의 개발로 펩티드 약물 접합체의 안정성과 효능이 향상되고 있습니다. 이러한 기술 혁신을 통해 다양한 임상 적용에 적합한 보다 강력하고 안전한 치료제를 개발할 수 있게 되었습니다.

맞춤형 의료와 정밀 종양학에 대한 관심이 높아진 것도 큰 원동력입니다. 개인 맞춤형 암 치료에 대한 수요가 증가함에 따라 개인의 유전자 프로파일과 종양 마커에 따라 치료를 조정하는 능력이 매우 중요해지고 있습니다. 펩티드 약물 접합체는 높은 특이성과 고유한 분자 마커를 표적으로 하는 능력을 가지고 있으며, 이러한 유형의 치료 접근법에 이상적으로 적합합니다. PDC는 보다 타겟화된 맞춤형 치료를 제공함으로써 암 치료의 효과를 높이고 부작용을 줄이며 시장 성장을 더욱 촉진할 것으로 기대됩니다. 새로운 펩티드 표적과 약물 조합에 대한 연구가 진행됨에 따라 PDC의 잠재적 용도가 확대되어 이 혁신적인 시장의 성장을 가속할 것으로 예측됩니다.

부문

제품 유형(Pluvicto, OctreoScan, Lutathera, Illuccix, 기타 제품 유형); 최종사용자(치료 최종사용자, 진단 최종사용자)

조사 대상 기업의 예

  • Angiochem Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics
  • Coherent Biopharma
  • Curium US LLC
  • Cybrexa Therapeutics
  • E. Merck KG
  • Ellipses Pharma
  • F. Hoffmann-La Roche Ltd
  • Hanmi Pharmaceuticals
  • Italfarmaco SpA
  • Novartis AG
  • Oncopeptides AB
  • PeptiDream Inc.
  • ProteinQure Inc.
  • Samsung Biologics
  • SignalChem Lifesciences
  • Soricimed Biopharma
  • Telix Pharmaceuticals Limited
  • Theratechnologies Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.18

Global Peptide Drug Conjugates Market to Reach US$9.5 Billion by 2030

The global market for Peptide Drug Conjugates estimated at US$3.6 Billion in the year 2024, is expected to reach US$9.5 Billion by 2030, growing at a CAGR of 17.5% over the analysis period 2024-2030. Pluvicto, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the OctreoScan segment is estimated at 18.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$986.0 Million While China is Forecast to Grow at 22.9% CAGR

The Peptide Drug Conjugates market in the U.S. is estimated at US$986.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 22.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.2% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global Peptide Drug Conjugates Market - Key Trends & Drivers Summarized

What Are Peptide Drug Conjugates and How Do They Work?

Peptide drug conjugates (PDCs) are a class of biopharmaceuticals that combine the therapeutic properties of peptides with the targeted delivery capabilities of drug molecules. These conjugates are formed by linking a bioactive peptide, which has high specificity for a particular receptor or biomarker, to a cytotoxic or therapeutic drug, typically via a stable chemical bond. The primary goal of PDCs is to enhance the effectiveness of treatments while minimizing side effects by ensuring that the drug is delivered directly to the site of action, such as a tumor or an infected tissue, via the peptide. This targeted delivery mechanism allows the drug to act specifically on the diseased cells while sparing healthy tissues, reducing systemic toxicity and enhancing therapeutic efficacy.

The use of peptides in PDCs is driven by their ability to selectively bind to specific cellular receptors, making them ideal candidates for targeted therapies. For instance, in cancer treatment, PDCs can be designed to deliver cytotoxic drugs directly to tumor cells that overexpress specific biomarkers, such as certain receptors or enzymes. By utilizing peptides that recognize these biomarkers, PDCs enable the targeted delivery of potent drugs, such as chemotherapy agents or immune modulators, thereby increasing the therapeutic index of the drug. PDCs have shown promise in oncology, autoimmune diseases, and infectious diseases, providing more effective and less toxic alternatives to traditional systemic drug therapies.

Why Is the Peptide Drug Conjugates Market Expanding?

The peptide drug conjugates market is experiencing rapid growth driven by several factors, including the increasing prevalence of cancer and other chronic diseases, the growing demand for targeted therapies, and advancements in peptide-based drug discovery. One of the most significant drivers of the market's expansion is the rising global burden of cancer. As traditional treatments such as chemotherapy and radiation therapy often cause severe side effects, there is a growing demand for therapies that are more precise and have fewer systemic effects. PDCs offer the potential to selectively target cancer cells, allowing for more effective treatment with fewer side effects compared to conventional chemotherapies.

The shift toward personalized medicine is another key factor fueling the growth of the peptide drug conjugates market. Personalized medicine involves tailoring treatments to individual patients based on their genetic makeup and the specific characteristics of their disease. Peptides, with their high specificity and ability to target unique biomarkers, are a perfect fit for personalized therapies. By using peptides that can recognize and bind to specific cancer cell markers or receptors, PDCs enable more effective treatment strategies tailored to the individual patient. This focus on personalized, targeted therapies is likely to continue driving interest and investment in peptide drug conjugates.

Advancements in peptide-based drug discovery and conjugation technologies are also contributing to the growth of the PDC market. As research in peptide synthesis and conjugation techniques continues to evolve, it is becoming easier and more cost-effective to develop peptides with high affinity for their targets. Additionally, improvements in linker chemistry, which connects the peptide to the drug molecule, have enhanced the stability, efficacy, and safety profile of PDCs. These advancements allow for the development of novel PDC therapies that can be used in a wide range of diseases, further expanding the potential applications of peptide drug conjugates.

What Key Trends Are Shaping the Future of Peptide Drug Conjugates?

The future of peptide drug conjugates is being shaped by several important trends, including advancements in peptide synthesis and conjugation technologies, the rise of combination therapies, and the expanding application of PDCs in non-oncology indications. One significant trend is the continued improvement in peptide synthesis and conjugation techniques. Advances in solid-phase peptide synthesis (SPPS) and automated conjugation methods are enabling the production of high-quality peptides and the development of more sophisticated PDCs. These advancements are also contributing to the scalability of peptide drug conjugates, allowing them to be manufactured more efficiently for clinical use.

Another key trend is the increasing use of PDCs in combination therapies. Combination therapies, where peptide drug conjugates are used alongside other treatment modalities such as immune checkpoint inhibitors, monoclonal antibodies, or conventional chemotherapy, are gaining momentum. These combinations are designed to improve the overall therapeutic outcome by targeting multiple pathways or enhancing the immune system’s ability to fight cancer. The synergistic effects of combining PDCs with other therapies could lead to improved response rates, reduced resistance, and better long-term outcomes, particularly in hard-to-treat cancers.

The expanding application of PDCs in non-oncology diseases is also shaping the future of this market. While PDCs have been primarily focused on oncology, there is growing interest in using them for the treatment of autoimmune diseases, infectious diseases, and even neurological disorders. The ability of peptide drug conjugates to specifically target disease sites in a more controlled manner opens new avenues for treating diseases that require highly targeted therapeutic interventions. As research into the broad applications of PDCs continues, we can expect to see these therapies being used in a wider variety of clinical indications.

What Are the Key Drivers of Growth in the Peptide Drug Conjugates Market?

The growth in the peptide drug conjugates market is driven by several key factors, including the increasing need for targeted therapies, advancements in peptide-based drug discovery, and the growing global demand for effective cancer treatments. One of the most important drivers is the increasing prevalence of cancer worldwide, which is prompting a shift toward therapies that can target cancer cells more selectively. Traditional chemotherapies, while effective, often cause significant side effects due to their lack of specificity. Peptide drug conjugates, by delivering drugs directly to the tumor site, offer the potential for more effective treatment with fewer side effects, making them highly attractive in the fight against cancer.

Advancements in peptide synthesis and drug conjugation technologies are also driving the market. Improved peptide synthesis techniques, including the development of more efficient and cost-effective production methods, have made it easier to create peptides with high specificity and affinity for target biomarkers. Additionally, the development of novel linker technologies that can more effectively conjugate drugs to peptides has enhanced the stability and efficacy of peptide drug conjugates. These innovations are enabling the creation of more potent and safe therapies that are suitable for a variety of clinical applications.

The increasing focus on personalized medicine and precision oncology is another major driver. As the demand for personalized cancer treatments rises, the ability to tailor therapies based on individual genetic profiles and tumor markers has become crucial. Peptide drug conjugates, with their high specificity and ability to target unique molecular markers, are ideally suited for this type of treatment approach. By providing more targeted and personalized therapies, PDCs are expected to improve the efficacy of cancer treatments and reduce adverse effects, further fueling the growth of the market. As research continues to uncover new peptide targets and drug combinations, the potential applications for peptide drug conjugates are expected to expand, driving further growth in this innovative market.

SCOPE OF STUDY:

The report analyzes the Peptide Drug Conjugates market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Pluvicto, OctreoScan, Lutathera, Illuccix, Other Product Types); End-Use (Therapeutic End-Use, Diagnostic End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Angiochem Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics
  • Coherent Biopharma
  • Curium US LLC
  • Cybrexa Therapeutics
  • E. Merck KG
  • Ellipses Pharma
  • F. Hoffmann-La Roche Ltd
  • Hanmi Pharmaceuticals
  • Italfarmaco SpA
  • Novartis AG
  • Oncopeptides AB
  • PeptiDream Inc.
  • ProteinQure Inc.
  • Samsung Biologics
  • SignalChem Lifesciences
  • Soricimed Biopharma
  • Telix Pharmaceuticals Limited
  • Theratechnologies Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Peptide Drug Conjugates - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Oncology Incidence Globally Spurs Demand for Targeted Peptide Drug Conjugates
    • Expanding Clinical Pipeline Throws the Spotlight on Late-Stage Candidates and Near-Term Commercialization
    • Precision Medicine Advancements Strengthen Business Case for Peptide-Based Therapeutics
    • Expanding Use of Peptide Drug Conjugates in Rare Diseases Expands Addressable Market Opportunity
    • Integration of AI and Machine Learning in Drug Design Drives Innovation in Peptide Conjugate Development
    • Biopharmaceutical Outsourcing Trends Propel Growth in CDMO Services for Peptide Conjugation
    • High Selectivity and Targeting Capabilities of Peptides Accelerate Demand in Precision Oncology
    • Government Funding for Cancer Research and Rare Disease Therapeutics Spurs Pipeline Expansion
    • Advances in Solid-Phase Peptide Synthesis Expand Manufacturing Scalability and Market Reach
    • Growing Focus on Antibody Alternatives Throws the Spotlight on Peptide Conjugates as Scalable Solutions
    • Emergence of Multifunctional Conjugates Expands Product Innovation Opportunities in Oncology and Beyond
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Peptide Drug Conjugates Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Peptide Drug Conjugates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pluvicto by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pluvicto by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pluvicto by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for OctreoScan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for OctreoScan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for OctreoScan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Lutathera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Lutathera by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Lutathera by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Illuccix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Illuccix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Illuccix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Therapeutic End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Therapeutic End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Therapeutic End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diagnostic End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Diagnostic End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Peptide Drug Conjugates by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Peptide Drug Conjugates by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Peptide Drug Conjugates by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Peptide Drug Conjugates by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Peptide Drug Conjugates by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • Peptide Drug Conjugates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Peptide Drug Conjugates by Product Type - Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Peptide Drug Conjugates by Product Type - Percentage Breakdown of Value Sales for Pluvicto, OctreoScan, Lutathera, Illuccix and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Peptide Drug Conjugates by End-Use - Therapeutic End-Use and Diagnostic End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Peptide Drug Conjugates by End-Use - Percentage Breakdown of Value Sales for Therapeutic End-Use and Diagnostic End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제